Innovent Starts China Trial of PI3Kδ Inhibitor for Indolent Lymphoma

Suzhou Innovent Bio, has dosed the first patient in a pivotal China Phase II registrational trial of parsaclisib, a novel and selective PI3Kδ inhibitor. The trial is aimed at testing the efficacy and safety of parsaclisib in patients with indolent lymphoma -- either recurrent/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). In 2018, Innovent acquired greater China rights from Incyte for three clinical-stage candidates, including parsaclisib. Incyte is already testing parsaclisib in several non-Hodgkin lymphomas and in myelofibrosis, diffuse large B-cell lymphoma and autoimmune hemolytic anemia. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //